Focus: ZyVersa Therapeutics is a public specialty pharmaceutical company headquartered in Florida focused on neurology and rare disease therapeutics. The company is in early-stage development with minimal commercial revenue and a lean operational footprint.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow ZyVersa Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for ZyVersa Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ZyVersa Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: ONCOLYTICS BIOTECH INC (ONCY) (CIK 0001129928) — 8-K
8-K
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
ZyVersa Therapeutics (ZVSA) Stock News - Stock Titan
ZyVersa Therapeutics (ZVSA) Stock News Stock Titan
ZyVersa biotech loses $1.8M in 3 months, left with $0.3M cash - Stock Titan
ZyVersa biotech loses $1.8M in 3 months, left with $0.3M cash Stock Titan
ZyVersa Therapeutics, Inc. 1Q 2026: Revenue $0 Net loss $1.79M — 10-Q Summary - TradingView
ZyVersa Therapeutics, Inc. 1Q 2026: Revenue $0 Net loss $1.79M — 10-Q Summary TradingView
ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 marketscreener.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo